Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Inclusion Criteria: * Previously untreated stage IV lung adenocarcinoma confirmed at MSKCC * Age 18 years or older * Karnofsky Performance Status ≥ 70 * Patients with locally treated, stable, and/or asymptomatic brain metastases are eligible. * Adequate bone marrow, liver and renal function, as specified below: * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L * Hemoglobin ≥ 8 g/dL * Platelets ≥ 100 x 109/L * Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome) * AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present * Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal. * Negative PPD test * For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment * Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter * Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors * Archival tissue (10 Unstained Slides - 5 micron sections) from a core biopsy performed and received within 30 days before signing consent or ability to have a fresh core biopsy performed * Biopsy cannot be from any cytology or bone specimen * Biopsy site must be amenable to re-biopsy at the end of the study * Ability to provide written, informed consent Exclusion Criteria: * Hypersensitivity to platinum agents * Ongoing use of investigational agents or use of investigational agents within the last four weeks * Prior use of agents for TNF-alpha blockade * History of rheumatoid arthritis, inflammatory bowel disease, or psoriatic arthritis * Baseline hearing deficit (CTCAE version 4.0 grade 2 or higher) * Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush * Active tuberculosis or untreated, latent tuberculosis o If a patient has signs, symptoms, or a history suggestive of active tuberculosis, evaluation by an infectious disease physician will be required and active tuberculosis ruled-out prior to enrollment. * Acute or chronic Hepatitis B or C infection * Known HIV infection requiring antiretroviral medications and those with AIDS * Active herpes zoster infection * Non-healed infected skin ulcers * History of myocardial infarction or unstable angina within the past 12 months * Ongoing use of other immunosuppressive medications, including oral steroids and excluding topical steroids * Women who are breastfeeding Prior history of other malignancy with the exclusion of localized prostate cancer, non-melanomatous skin cancer, ductal carcinoma or lobular carcinoma in situ of the breast